
Long-Term Study Confirms Sustained Efficacy and Safety of Zigakibart in IgA Nephropathy Patients
In a significant advancement for the treatment of IgA nephropathy (IgAN), recent findings from a 100-week Phase 1/2 clinical trial have highlighted the promising long-term efficacy and safety profile of zigakibart, an investigational monoclonal …